Lineage Cell Therapeutics Inc (LCTX): Bathi sing dikarepake

Lineage Cell Therapeutics (LCTX) relies on stable medical demand, yet faces risks due to its dependence on chemical imports. The creation of drugs requires manual physician control, despite partial automation of synthesis. The company's target profit level on GURU.Markets yields 0.03, which characterizes this valuation parameter. Currently, AI-driven robots are being implemented in clean rooms for the precise dosing of biomaterials.

Lineage Cell Therapeutics (LCTX): Bathi sing dikarepake saka 04.07.2022 nganti 28.08.2022

Rincian metrik komprehensif lan analitis Lineage Bio (LCTX)

- rega saham lan konsensus proyeksi valuasi:

Rega saham Lineage Corp|LCTX - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar Lineage Cell Therapeutics Inc|LCTX - Nilai Total Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham Lineage Cell Therapeutics|LCTX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku lineagecell.com|LCTX - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas Lineage Cell Therapeutics|LCTX - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal lineagecell.com|LCTX - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Lineage Corp|LCTX - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lineage Cell Therapeutics|Rasio cepet lineagecell.com

- data bathi resik lan rasio valuasi:

LCTX - Bathi resik|Proyeksi bathi mangsa ngarep Lineage Cell Therapeutics|LCTX - Rasio kapitalisasi marang bathi resik|Pangali Forward P/E lineagecell.com|LCTX - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lineage Bio|LCTX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Lineage Cell Therapeutics|LCTX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan lineagecell.com|LCTX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Lineage Cell Therapeutics

- statistik dodolan lan pendapatan perusahaan:

LCTX - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Lineage Cell Therapeutics, Inc.|LCTX - Rasio rega marang pendapatan|Multiplikator forward rega marang pendapatan Lineage Bio|LCTX - Dinamika pendapatan YoY sajrone rolas wulan kepungkur

Analisis wiwitan perusahaan:LCTX, Lineage Bio

Barang utama Lineage Cell Therapeutics Inc

Advancing regenerative medicine for the restoration of the CNS and vision, Lineage Cell Therapeutics (LCTX) is scaling its market share through successes in retinal therapy. The current value of 0.03 reflects the consensus of expected revenues, adjusted for past distortions, allowing investors to assess the business model's resilience to external shocks and verify the asset's risk profile through the company's projected revenue trend.

Perusahaan pesaing

MESO (Mesoblast Pharma) - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake Surrozen Inc SRZN|Bathi sing dikarepake Cryo-Cell International, Inc. (CCEL)|Bathi sing dikarepake FBLG (FibroBiologics Inc.)|Bathi sing dikarepake Longeveron Inc. LGVN|BioRestorative Therapies - Bathi sing dikarepake|CELZ - Bathi sing dikarepake